On Minimizing Risk and Harm in the Use of Psychedelic

Psychedelic drugs, defined here as classic serotonergic compounds such as psilocybin, LSD, mescaline and DMT, are presented as having therapeutic potential but also carrying distinct risks. The authors note that a minority of non-clinical users—about 9%—report functional difficulties lasting longer than a day after acute effects, and that some post-psychedelic problems can persist for weeks, months or years. Risks appear lower in clinical trials, likely because of screening and controlled conditions, yet serious adverse events (AEs) still occur and some AEs may be under-reported. The paper places these concerns in the broader context that all effective psychotropic treatments have AE profiles and that psychotherapeutic components can themselves produce adverse responses; combined drug-plus-psychotherapy approaches therefore require monitoring of both pharmacological and interpersonal harms. This article responds to gaps in knowledge about the types, predictors and treatments of psychedelic harms and about how best to support people who experience post-psychedelic difficulties. It aims to synthesise the perspectives of 30 psychedelic researchers to identify critical research priorities and practical steps for creating a more robust ‘psychedelic safety net’, including improved surveillance, better support services, clearer public communication, and targeted funding mechanisms to reduce risk during wider implementation and scale-up.

Evans and colleagues surveyed 30 psychedelic researchers, who are listed as co-authors on the paper, via an online questionnaire to elicit perceived critical research gaps concerning psychedelic safety, harms and harm reduction. The extracted text reports that respondents were asked to identify key gaps but does not provide specific details about the survey instrument, question format, sampling or recruitment procedures, timing, or the analytic approach used to collate and synthesise responses. Because the extraction does not report quantitative analysis methods or coding procedures, it appears the paper presents a consensus-style summary of the main themes that emerged from the researchers’ responses rather than a formal qualitative content analysis with inter-rater reliability metrics. The Methods section does not clearly specify whether any systematic ranking or weighting of priorities was performed, nor does it describe participant characteristics beyond their status as psychedelic researchers.

The survey responses converged on several interrelated priorities for research, practice and policy. First, respondents emphasised the need to define and characterise the main types of psychedelic-related harms. Emerging evidence and the authors’ synthesis identify harms that can extend beyond the acute drug effect, including emotional problems (for example anxiety, depression and affective dysregulation) and more severe events such as manic/hypomanic or psychotic episodes. The extraction notes the prevalence estimate of 9% for non-clinical users experiencing functional difficulties lasting more than a day, and it highlights that psychotherapeutic adverse-event rates in general range from 7% to 15%, underscoring the importance of monitoring both drug-related and interpersonal harms. Second, the researchers called for improved ability to predict who is at risk and to develop appropriate a priori safeguards. Screening tools and risk-factor research were highlighted as scarce and necessary. Third, there was widespread agreement on the value of post-psychedelic “integration” psychotherapy or support to reduce harms and enhance benefit; however, the authors stress that research on integration models is very limited and not yet evidence-based. Several research groups are developing psychometric instruments to evaluate psychedelic-specific adverse events, and the investigators recommend that clinical trials and legal treatment programmes adopt and further validate such instruments and extend monitoring periods where possible to enable comparability of long-term outcome data. Fourth, practical support needs were emphasised: better online information, peer support groups, affordable therapy, access to psychiatric consultation and medication, and government-funded public health education. The extraction notes that some people recovering from post-psychedelic difficulties find non-judgemental therapy helpful, while others report poor experiences with integration therapists who employ dogmatic messaging such as “trust the medicine.” Finally, the respondents argued for more accurate and balanced public communication by researchers, companies, institutions, investors, campaigners and media, coupled with robust informed-consent processes that transparently convey risks without unduly priming recipients. Systemic barriers singled out include the continuing illegality of most psychedelics and lack of government investment in safety research and public education. As a pragmatic funding proposal, the authors suggest that psychedelic philanthropists, investors and companies could commit 1% of their investments to support research, education and support services; they offer the U.S. Human Genome Research funding precedent (3% to Ethical, Legal and Social Implications research) as an analogue. The paper also recommends post-marketing surveillance to detect AEs that may arise during broader implementation.

The investigators interpret their survey findings as a call for coordinated, collaborative work to build a better psychedelic safety net. They argue that the field needs clearer typologies of harm, stronger predictive models to screen and safeguard people before treatment, validated instruments for monitoring psychedelic-specific adverse events, and longer follow-up in trials and treatment programmes to capture delayed or persistent problems. Integration practices are seen as promising but under-researched, so the authors urge systematic evaluation of different models of post-psychedelic support. In positioning these recommendations relative to earlier research, the paper notes consistency with prior observations that some adverse outcomes occur more frequently outside controlled settings and that certain harms may only become apparent postapproval or during Phase IV surveillance. The authors acknowledge limitations in the evidence base, including sparse empirical data on integration therapies and concerns about under-reporting of AEs in trials. They also highlight practical obstacles such as legal restrictions and limited public funding for safety research. For practice and policy, the researchers recommend multifaceted measures: improved clinician and public education about potential harms, accessible support services (including non-dogmatic therapeutic options and peer networks), adoption and validation of standardised AE measurement tools, enhanced post-marketing surveillance, and targeted funding commitments from the private sector and philanthropists to fill gaps where governments do not invest. The authors present these steps as achievable and likely to enhance the safe real-world deployment of psychedelic-assisted therapies without claiming definitive solutions.